Serotype-specific inhibition of bacterial clearance by free CPSs. (A) Blocking effect of free CPS19F and CPS23F on the clearance of homologous serotypes of pneumococci were assessed as in Fig. 7 B. n = 6. (B) Impact of free LV CPSs on elimination of homologous serotypes of pneumococci during the first 30 min of infection. n = 3–6. (C) Impact of free CPS3, CPS6A, and CPS8 on the clearance of homologous serotype derivatives of TH870 was assessed as in A. n = 3–6. (D) Same as B except using HV CPSs. n = 3–6. (E) Survival of mice infected i.v. with 104–106 CFU of serotype-3 pneumococci. n = 5. (F) Impact of CPS3 on the clearance of sublethal dose (105 CFU) of serotype-3 pneumococci during the first 30 min of infection. n = 3. (G) Clearance rates of serotype-14 pneumococci in mice pretreated with one of the eight free CPSs (400 μg/mouse) before i.v. infection with 106 CFU. n = 3–6. (H) Clearance rates of serotype-19F pneumococci in mice pretreated with each type of free CPSs (400 μg/mouse) before i.v. infection with 106 CFU. n = 3–6. (I) Same as H except using serotype-23F pneumococci as an inoculum. n = 3–6. All mice were used on a CD1 background. Data were pooled from two independent experiments, except F (one experiment). Two-way ANOVA with Tukey’s (A, left and middle panels) and Sidak’s (A, right panel, B, and D) multiple comparisons test, Ordinary one-way ANOVA with Tukey’s multiple comparisons test (G–I), **, P < 0.01, ***, P < 0.001, ****, P < 0.0001.
